September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinical Trial presentations highlighting the latest cardiovascular science. ESC 2017 includes 21 late-reaking clinical trials, presented and discussed in four Hot Line sessions, plus late breaking results from 12 registries and 12 clinical trial updates. Some of the key presentations with links to the article were:

The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast agents, injected in a patient's veins to brighten tissues in MRI images, accumulate in the brain. More than 300 million doses of such drugs have been administered since their introduction in 1987.

Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) in July to initiate a pivotal clinical trial of the SurVeil drug-coated balloon (DCB). The randomized trial will evaluate the SurVeil DCB for treatment for peripheral artery disease (PAD) in the upper leg compared to the Medtronic IN.PACT Admiral DCB.

Aug. 15, 2017 – Patients undergoing percutaneous coronary intervention (PCI) at safety-net hospitals experienced similar outcomes as patients treated at non-safety-net hospitals, according to research published Aug. 7 issue of JACC: Cardiovascular Interventions. Read the abstract.

Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc. (VDI) investigational device exemption (IDE) study so it can initiate its pivotal trial for its MobiusHD System for the treatment of resistant hypertension.

Aug. 10, 2017 — The American College of Radiology (ACR) developed three new guidance documents and revised 32 others to advance the science of radiology and improve the quality of service to patients.

Aug. 15, 2017 — The U.S, Food and Drug Administration (FDA) granted market clearance for the HAART 200 Aortic Annuloplasty Device, the first annuloplasty device designed specifically for bicuspid aortic valve repair. With FDA clearance of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable Science and Engineering Inc. is now able to offer U.S. surgeons a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency. 

Hypertrophic Cardiomyopathy (HCM) Summit

Read an updated version of this article with more detail from CMS — "CMS to Cancel Mandatory Cardiac Bundled Payments and Cardiac Rehabilitation Payment Model."
 

Aug. 14, 2017 — The Centers for Medicare and Medicaid Services (CMS) may eliminate the cardiac rehabilitation incentive payments and orthopedic bundled payments that were planned to go into effect Jan. 1, 2018. 

Cardiology Fiesta Symposium

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now